Skip to content

Search Results

No Matching Results

    Recently Viewed

      Listening...

      HomeLatest newsWhat you need to know about Johnson & Johnson’s 2022 second-quarter earnings
      Illustration of people examining large charts and graphs

      What you need to know about Johnson & Johnson’s 2022 second-quarter earnings

      Check out this infographic breakdown of the company’s second-quarter 2022 performance, with key highlights from its Pharmaceutical, MedTech and Consumer Health businesses.

      Share Article
      share to
      q1-2022-quarterlyearnings-0422.png

      This morning, Johnson & Johnson shared its second-quarter performance.

      Since its founding in 1886, the company has grown to become one of the world’s largest and most broadly based healthcare companies, with approximately 144,000 employees across the globe working every day to help change the trajectory of health for humanity.

      “We are proud to have delivered on the robust operational guidance that we set forth at the beginning of the year, as we’ve continued to advance breakthrough innovation and foster patient access to make a positive impact across many areas of healthcare,” says Joe Wolk, Executive Vice President and Chief Financial Officer, Johnson & Johnson. “Johnson & Johnson is strongly positioned to continue making progress on our business priorities, including the creation of the New Consumer Health Company, to deliver both near- and long-term value to all of our Credo stakeholders.”

      For more details about the company’s 2022 second-quarter results, and to read a message from Chief Executive Officer Joaquin Duato, here’s an infographic that highlights key stats.


      Johnson & Johnson Q2 2022 earnings infographic

      Want to see more company earnings information? Find Johnson & Johnson’s past quarterly and full-year results here.

      More from Johnson & Johnson

      Meet a nurse who leads clinical trials to find innovative cancer therapies

      Melissa Martinez is a clinical scientist within Johnson & Johnson’s Interventional Oncology R&D group. Not only is she helping to develop lifesaving treatments, she’s redefining what it means to pursue a career in nursing.

      What’s the difference between IBS and IBD?

      These GI conditions sound similar, and they also share some symptoms. But IBS and IBD are distinct disorders—especially when it comes to treatment and the risk of complications.

      What is IL-23?

      This pro-inflammatory protein is the target of potential Johnson & Johnson medications that could help treat autoimmune conditions such as psoriasis, inflammatory bowel disease and rheumatoid arthritis.
      You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.